الصفحة الرئيسية>>Peptides>>Angiopep-2 hydrochloride

Angiopep-2 hydrochloride

رقم الكتالوجGC61479

Angiopep-2 هيدروكلوريد هو ناقل ببتيد في المخيمكن أن يؤدي اقتران العوامل المضادة للسرطان مع ناقل الببتيد Angiopep-2 إلى زيادة فعاليتها في علاج سرطان الدماغ

Products are for research use only. Not for human use. We do not sell to patients.

Angiopep-2 hydrochloride التركيب الكيميائي

الحجم السعر المخزون الكميّة
1 mg
130٫00
متوفر
5 mg
371٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer[1].

Paclitaxel is conjugated to a brain peptide vector, Angiopep-2, to provide a paclitaxel- Angiopep-2 conjugate named ANG1005. ANG1005 enters the brain to a greater extent than paclitaxel and bypasses the P-gp. ANG1005 has an antineoplastic potency similar to that of paclitaxel against human cancer cell lines[1].

ANG1005 administration leads to a significant increase in the survival of mice with intracerebral implantation of U87 MG glioblastoma cells or NCI-H460 lung carcinoma cells[1].

[1]. A RÉgina, et al. Antitumour Activity of ANG1005, a Conjugate Between Paclitaxel and the New Brain Delivery Vector Angiopep-2. Br J Pharmacol. 2008 Sep;155(2):185-97.

مراجعات

Review for Angiopep-2 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Angiopep-2 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.